Get real time updates directly on you device, subscribe now.
Fundly.ai, a Mumbai-based B2B startup, has raised $4 million in an equity round led by existing investors Accel and Multiply. The company also secured around $0.9 million in venture debt, giving it additional capital to grow its services for pharmaceutical retailers and distributors.
Pharma distribution is the network that helps medicines move from manufacturers to distributors, pharmacies, and finally patients. Fundly.ai is trying to make this chain easier to manage through digital ordering, payments, and access to business credit.
What Fundly.ai does
Fundly.ai was founded in 2021 by Amit Chawla and Shreeram Ramanathan.
It began as a supply-chain finance platform for pharmaceutical businesses and has expanded into three connected areas – B2B commerce, payment and settlement tools, and embedded credit.
B2B means business-to-business. Fundly.ai does not sell medicines directly to consumers. Instead, it serves pharmacies, distributors, stockists, and other businesses involved in medicine distribution.
A pharmacy owner may need to buy stock before receiving payment from customers. This can create a cash-flow gap, especially when demand rises for certain medicines. Fundly.ai aims to help businesses arrange working capital, compare buying options, place orders, and track payments in one place.
Why the fresh funding is important
The company plans to use the new funding to widen its commerce, payments, and credit offerings across India’s pharma supply chain. This is a logical next step because finance alone cannot solve every daily problem of a distributor or retailer.
For instance, a distributor may be managing supplier payments, inventory purchases, pending collections, and credit repayments at the same time. Using separate calls, spreadsheets, and paper records can slow things down. A connected platform can bring these tasks closer together and give businesses a clearer picture of money coming in and going out.
Fundly.ai says it has served more than 4,100 retailers and distributors across over 600 PIN codes and 24 cities since its launch. As with any growing fintech business, maintaining strong credit checks and timely support will be important as it expands.
The startup’s larger aim
Fundly.ai is betting on a simple idea – a smoother pharma supply chain can help smaller businesses operate with more confidence. Better payment tracking, clearer purchasing data, and accessible credit may help retailers avoid stock shortages or missed payment deadlines.
The startup’s aim is not only to lend money. It wants to become a daily operating platform for pharma trade, where commerce and financial activity work together. That could make its service more useful than a standalone loan product.
Competition in the pharma B2B space
Pharmarack is a major player in India’s pharma B2B market. Its platform offers digital ordering, inventory visibility, data tools, and services for retailers, distributors, and pharma companies.
Fundly.ai’s edge may come from its sharper focus on the connection between procurement, payments, and working capital. Pharmarack has a broad trade and data network, while Fundly.ai is building a finance-led operating layer for smaller and mid-sized pharma businesses. Both are addressing the same larger need – making a fragmented medicine distribution system more organized.
Key takeaways –
Fundly.ai’s $4 million funding round shows investor interest in technology that supports the everyday financial needs of India’s pharma trade. Accel and Multiply’s continued backing gives the startup room to improve its products and reach more businesses.
The company’s real test will be execution. If Fundly.ai can make buying, paying, and borrowing simpler for pharmacies and distributors, it could become a useful part of the country’s healthcare supply chain.
Facts Input- BW Disrupt
Discover more from Newskart
Subscribe to get the latest posts sent to your email.
